載入中
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
收盤時
US$23.40
−US$0.28 · -1.18%
盤後
US$23.40
US$0.00 · 0.00%
10月12日 下午4:04 ET
盤中時間採用ET。市場資料可能有所延遲。
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
日內區間
目前US$23.40
52週區間
目前US$23.40
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
持有
估值
45
合理估值
情緒
49
多空交錯
風險
54
風險偏高
動能
70
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
日內區間
目前US$23.40
52週區間
目前US$23.40
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（EUR） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2964.3萬 EUR | −719萬 EUR | 3620.8萬 EUR | 477.6萬 EUR | 264.7萬 EUR |
| 毛利 | 2964.3萬 EUR | −719萬 EUR | 3620.8萬 EUR | 477.6萬 EUR | 264.7萬 EUR |
| 研究與開發 | 2311.5萬 EUR | 4054.1萬 EUR | 3839.6萬 EUR | 3263.6萬 EUR | 3037.8萬 EUR |
| 銷售、一般及管理費用 | 2022.2萬 EUR | 2052.7萬 EUR | 2204.9萬 EUR | 1785.7萬 EUR | 1943.4萬 EUR |
| 營業費用 | 4046.1萬 EUR | 6120.2萬 EUR | 6298.7萬 EUR | 5147.8萬 EUR | 5522.6萬 EUR |
| 利息收入 | 98.5萬 EUR | 262.9萬 EUR | 121.7萬 EUR | 25.6萬 EUR | — |
| 利息支出 | 1039.5萬 EUR | 808.6萬 EUR | 798.2萬 EUR | 583.7萬 EUR | 69.95萬 EUR |
| 折舊和攤銷 | 149.5萬 EUR | 162.1萬 EUR | 151.3萬 EUR | 150萬 EUR | 156萬 EUR |
| 營業利益 | −1081.8萬 EUR | −6839.2萬 EUR | −2677.9萬 EUR | −4670.2萬 EUR | −5257.9萬 EUR |
| 淨利 | −2396.1萬 EUR | −6813.2萬 EUR | −3970萬 EUR | −5704.1萬 EUR | −4700.3萬 EUR |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
評級樣本有限，僅4項
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
